| André Choulika |
André Choulika is the founder. He founded Cellectis SA in 1999 and currently holds the title of Chief Executive Officer & Director. He also founded Calyxt, Inc. in 2010 and served as Chairman until 2020. In addition to his founding positions, Dr. Choulika currently holds several other roles. Since 2014, he has been the Chairman & Chief Executive Officer of Cellectis, Inc. He also serves as Chairman & Chief Executive Officer of Cellectis Biologics, Inc. since 2019. Furthermore, Dr. Choulika is the Director of Institut Pasteur and a Director of the France Biotech Association. Previously, Dr. Choulika held a position as Director at Takara Bio Europe AB. Dr. Choulika obtained his doctorate degree from Université Pierre et Marie Curie in 1995. |
| Mark Frattini |
Mark Frattini is currently the Chief Medical Officer at Cellectis SA. He previously worked as the Director-Research at The Trustees of Columbia University in The City of New York from 2013 to 2018. Mark also held the position of Executive Medical Director at Celgene SAS and was a Member-Adult Leukemia Service at Memorial Sloan Kettering Cancer Center. He obtained a doctorate degree from The University of Chicago. |
| Stephan Reynier |
Stephan Reynier currently works at Cellectis SA, as Chief Regulatory & Compliance Officer from 2011. Mr. Reynier also formerly worked at Gilead Sciences, Inc., as Associate Medical Affairs Director-European Region from 2002 to 2006, Voisin Consulting, Inc., as Senior Director, Takara Bio Europe AB, as Head-Project Management & Regulatory Affairs, and Ectycell SASU, as Head-Programs from 2011 to 2014. Mr. Reynier received his graduate degree from the University of Toronto. |
| Philippe Duchateau |
Philippe Duchateau has worked as the Chief Scientific Officer at Cellectis SA since 2012. |
| Kyung Nam-Wortman |
Kyung Nam-Wortman is currently the Chief Human Resources Officer & Executive VP at Cellectis SA since 2020. Prior to this, from 2014 to 2020, Ms. Nam-Wortman was the Senior Vice President & Head-Human Resources at Achillion Pharmaceuticals, Inc. Before that, Ms. Nam-Wortman was the Vice President & Head-Global Talent Management at Zoetis, Inc. Ms. Nam-Wortman has a graduate degree from The New School for Social Research and an undergraduate degree from The Leonard N Stern School of Business. |
| Arthur Stril |
Arthur Stril is currently the Chief Financial & Business Officer at Cellectis SA. He is also a Member at Corps des Mines. Mr. Stril has an undergraduate degree from École Normale Supérieure and a graduate degree from the University of Cambridge. |
| David J. Sourdive |
David J. Sourdive is the founder. He founded Cellectis SA in 1999 and holds the title of Director & Executive VP-CMC & Manufacturing. Dr. Sourdive is also the founder of Bilhi Genetics SAS. Dr. Sourdive's current job(s) include being the Chairman of Mablink Bioscience SAS, a Director at Exeliom Biosciences, a Director at Cell-Easy SAS since 2021, and a Venture Partner at Elaia Partners SAS since 2019. Dr. Sourdive's former job(s) include being the Chairman & Chief Executive Officer of Takara Bio Europe AB, the President & Chief Executive Officer of Ectycell SASU from 2009 to 2012, and a Director at Medicen Paris Region, Cellectis AB, Département de la Seine-Saint-Denis (France), Mediterranean Institute For Life Sciences, EnobraQ SAS from 2018 to 2021, Eukarys SAS from 2015 to 2019, and Omics SAS from 2017 to 2020. Dr. Sourdive's education history includes studying at Ecole Polytechnique as an undergraduate. |
| Jean-Pierre Garnier |
Jean-Pierre Garnier is currently the Non-Executive Chairman at Cellectis SA, a Director at Carrier Corp., an Independent Director at Carrier Global Corp., and an Operating Partner at Advent International LLC. Previously, he held positions such as Chief Executive Officer at Smithkline Beecham Plc, Chief Executive Officer & Executive Director at GSK Plc, Chief Executive Officer at Pierre Fabre SA, Chairman at NormOxys, Inc., Chairman at Alzheon, Inc., Chairman at ABIONYX Pharma SA, Non-Executive Chairman at Carmat SA, Chairman at Idorsia Ltd., Non-Executive Chairman at Idorsia Pharmaceuticals Ltd., and Independent Director at United Technologies Corp. He also served as an Independent Director at Radius Health, Inc., Renault SA, Actelion Ltd., Pierre Fabre Participations SAS, Cerenis Therapeutics, Inc., and Weill Cornell Medical College. Additionally, he was a Director at Max Planck Institute For Biophysical Chemistry and President at Schering-Plough Corp. He started his career as the President of e.Nvizion Communications Group Ltd. He has also served as a Trustee at Newman's Own Foundation and a Trustee at Max Planck Florida Institute for Neuroscience. Dr. Garnier obtained an MBA from Stanford University and completed graduate and doctorate degrees from Louis Pasteur University. |
| Rainer J. Boehm |
Rainer J. Boehm is the founder of Rainer Boehm GmbH. He currently holds multiple positions, including Chairman at Berlin Cures Holding AG, Independent Director at Humanigen, Inc., Independent Director at Cellectis SA, Independent Director at Omega Therapeutics, Inc., and Director at BioCopy AG. Previously, he served as the Chief Executive Officer & Head-Pharma Division at Novartis Pharma SAS. He was also an Independent Director at Nordic Nanovector ASA from 2018 to 2022. From 2005 to 2010, he held the position of Executive Vice President-North America at Novartis Oncology, Inc. Additionally, he served as the Chief Commercial & Medical Affairs Officer at Novartis Pharma Schweiz AG from 2010 to 2017. Dr. Boehm obtained a doctorate degree from Universität Ulm and an MBA from Schiller International University (France). |
| Donald A. Bergstrom |
Donald A. Bergstrom is currently an Independent Director at Cellectis SA and a Director at Cellectis, Inc. He is also the President-Research & Development at Relay Therapeutics, Inc. Previously, he served as an Independent Director at Fusion Pharmaceuticals, Inc. from 2021 to 2024. Prior to that, he was the Chief Medical Officer & Senior Vice President at Mersana Therapeutics, Inc. from 2014 to 2018. He also held the position of Global Head-Translational & Experimental Medicine at Sanofi-Aventis U.S. LLC from 2010 to 2014. Additionally, he worked as a Principal at Merck Research Laboratories Massachusetts LLC and as the Global Head-Translational Medicine at Genzyme Therapeutics Ltd. from 2010 to 2014. Dr. Bergstrom holds a doctorate degree from the University of Washington and an undergraduate degree from The Johns Hopkins University. |
| Axel-Sven Malkomes |
Axel-Sven Malkomes is currently an Independent Director at Cellectis SA and a Managing Director at Medigene Immunotherapies GmbH. Previously, he worked as Vice Chairman & MD-Life Sciences Practice at Barclays PLC from 2016 to 2019, as a Director at 3i Deutschland Gesellschaft für Industriebeteiligungen mbH, as Head-Strategy Planning at Merck KGaA, and as Global Head-Healthcare & Chemicals Investment at Société Générale SA from 2010 to 2016. He also served as Chief Financial & Business Development Officer at MediGene AG from 2019 to 2022. |
| Pierre Bastid |
Pierre Bastid is currently the Chairman of Babalia SA and a Director of The Grid, Nepteam SAS, Downtown Community Television Center, Shango NV, Crystal Sunrise SA, Hebioso SA, Les Bastidons SA, Kotys SA, Hougou Finance SA, Batuque Hotelaria E Turismo SA, Evok Hotels Collection, Louise 342-344 SA, Zaka, Nepteam, and a Trustee of The Juilliard School. He is also an Independent Director of Cellectis SA and Carmat SA. In the past, he served as the Chairman, President & Chief Executive Officer of GE Energy Power Conversion Group SAS and as the President & Chief Executive Officer of GE Energy Power Conversion USA, Inc. He was also the Chairman-Supervisory Board of GE Energy Power Conversion GmbH and the Chairman of Zodiac International SAS. He has also served as a Director of Pharnext SA and Casino Royal S.A. He received his undergraduate degree from INSEAD and Ecole Centrale Lyon. |
| Laurent Arthaud |
Laurent Arthaud is currently the Chairman-Supervisory Board at Argobio SAS. He is also an Independent Director at Cellectis SA, a Director at Kurma Partners SA, Aledia SAS, ENYO Pharma SA, SparingVision SAS, and Ribogenics, Inc. Mr. Arthaud previously served as the Deputy General Manager at BPIFrance Investissement SAS. He has also held positions as the Deputy Chief Executive Officer at CDC Croissance SA, President & Chief Executive Officer at Pharmavent Partners, Director at IntegraGen SA, Independent Director at SCYNEXIS, Inc., Director at Demeter Ventures SA, Director at Sangamo Therapeutics France SAS, Director at Adocia SA, Director at Calyxt, Inc., Director at Emertee Gestion, and Vice President at Aventis Capital. Mr. Arthaud received his undergraduate degrees from Ecole Polytechnique in 1984 and Ecole Nationale de la Statistique & de l'Administration in 1986. |
